The Combination of Anti-Thymocyte Globulin and Basiliximab for Haploidentical Hematopoietic Stem Cell Transplantation
PDF

Keywords

Basiliximab
Anti-Thymocyte Globulin
Haploidentical Hematopoietic Stem Cell Transplantation

Categories

How to Cite

1.
Wang F, Luo Y, Zhang Y, Lou S, Zhou K, Chen S, Zeng H, Shen Y, Deng J. The Combination of Anti-Thymocyte Globulin and Basiliximab for Haploidentical Hematopoietic Stem Cell Transplantation. Integr J Med Sci [Internet]. 2021 Mar. 17 [cited 2022 May 16];8. Available from: https://www.mbmj.org/index.php/ijms/article/view/474

Abstract

Objectives: Identical hematopoietic stem cell transplantation (haplo-HSCT) is associated with a higher risk of graft rejection when compared to matched sibling donor transplantations. Methods: The study included 34 patients who were treated with a novel regimen combining basiliximab, Anti-thymocyte globulin (ATG) and conventional immunosuppressive in the recipients of haplo-HSCT. Results: The cumulative incidence of grade II–IV and grade III–IV aGVHD was 38.2% and 11.8%, while the rates of limited and extensive cGVHD were 17.6% and 23.5%, respectively. Laboratory evidence of CMV and EBV reactivation were found in 9 patients (26.5%) and 6 patients (18.8%), respectively. The relapse rate of haplo-HSCT was 14.7% at 1 year; and 1-year OS and DFS were achieved in 58.8% and 55.9% of the patients, respectively. Conclusions: The results suggested that basiliximab combined with low-dose ATG could be a promising treatment strategy in haplo-HSCT.

https://doi.org/10.15342/ijms.2021.474
PDF

References

Morishima Y, Sasazuki T, Inoko H, Juji T, Akaza T, Yamamoto K, et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood. 2002 Jun 1;99(11):4200-6. https://doi.org/10.1182/blood.v99.11.4200

Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985 Sep 26;313(13):765-71. https://doi.org/10.1056/nejm198509263131301

Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, et al. Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant. Blood. 1997 May 15;89(10):3864-72. https://doi.org/10.1182/blood.V89.10.3864

Shin DY, Lee JH, Park S, Lee JO, Moon JH, Ahn JS, et al. Role of thymoglobulin in matched sibling allogeneic hematopoietic stem cell transplantation with busulfan and fludarabine conditioning in myeloid malignanicies. Bone Marrow Transplant. 2018 Feb;53(2):207-212. https://doi.org/10.1038/bmt.2017.240

Lee KH, Lee JH, Lee JH, Kim DY, Park HS, Choi EJ, et al. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission. Biol Blood Marrow Transplant. 2017 Sep;23(9):1555-1566. https://doi.org/10.1016/j.bbmt.2017.05.025

Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016 Jan 7;374(1):43-53. https://doi.org/10.1056/nejmoa1506002

Kalra A, Williamson T, Daly A, Savoie ML, Stewart DA, Khan F, et al. Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 Sep;22(9):1654-1663. https://doi.org/10.1016/j.bbmt.2016.05.020

Chang YJ, Wang Y, Mo XD, Zhang XH, Xu LP, Yan CH, et al. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. Cancer. 2017 Aug 1;123(15):2881-2892. https://doi.org/10.1002/cncr.30540

Xu LP, Zhang CL, Mo XD, Zhang XH, Chen H, Han W, et al. Epstein-Barr Virus–Related Post-Transplantation Lymphoproliferative Disorder after Unmanipulated Human Leukocyte Antigen Haploidentical Hematopoietic Stem Cell Transplantation: Incidence, RiskFactors, Treatment, and Clinical Outcomes. Biol Blood Marrow Transplant. 2015 Dec;21(12):2185-2191. https://doi.org/10.1016/j.bbmt.2015.07.035

Wang Y, Fu HX, Liu DH, Xu LP, Zhang XH, Chang YJ, et al. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant. 2014 Mar;49(3):426-33. https://doi.org/10.1038/bmt.2013.191

Liu J, Xu LP, Bian Z, Chang YJ, Wang Y, Zhang XH, et al. Differential impact of two doses of antithymocyte globulinconditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. J Transl Med. 2015 Dec 30;13:391. https://doi.org/10.1186/s12967-015-0748-x

Grüllich C, Ziegler C, Finke J. Rabbit Anti T-Lymphocyte Globulin Induces Apoptosis in Peripheral Blood Mononuclear Cell Compartments and Leukemia Cells, While Hematopoetic Stem Cells Are Apoptosis Resistant.Biology of Blood & Marrow Transplantation, 2009, 15(2):173-182. https://doi.org/10.1016/j.bbmt.2008.11.014

Bacigalupo A. Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplantat. 2005 Feb;35(3):225-31. https://doi.org/10.1038/sj.bmt.1704758

Depper J M. Blockade of the interleukin-2 receptor by anti-Tac antibody: inhibition of human lymphocyte activation. J Immunol. 1983 Aug;131(2):690-6.

Huang R, Tu S, Deng L, Kang Q, Song C, Li Y. et al. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis. Hematology. 2015 Jul;20(6):313-9. https://doi.org/10.1179/1607845414y.0000000207

Ji SQ, Chen HR, Yan HM, Wang HX, Liu J, Zhu PY, et al. Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies. Bone Marrow Transplant. 2005 Aug;36(4):349-54. https://doi.org/10.1038/sj.bmt.1705046

Zhang R, Shi W, Wang HF, You Y, Zhong ZD, Li WM, et al. Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia. Bone Marrow Transplant. 2017 Sep;52(9):1253-1260. https://doi.org/10.1038/bmt.2017.100

Basara N, Roemer E, Kraut L, Guenzelmann S, Schmetzer B, Kiehl MG, et al. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience. Bone Marrow Transplant. 2002 Nov;30(10):651-9. https://doi.org/10.1038/sj.bmt.1703697

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man: A long-term clinicopathologic study of 20 seattle patients. Am J Med. 1980 Aug;69(2):204-17. https://doi.org/10.1016/0002-9343(80)90380-0

Tan Y, Xiao H, Wu D, Luo Y, Lan J, Liu Q, et al. Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study. Oncoimmunology. 2017 Jan 6;6(3):e1277307. https://doi.org/10.1080/2162402x.2016.1277307

Chakupurakal G, García-Márquez MA, Shimabukuro-Vornhagen A, Theurich S, Holtick U, Hallek M, et al. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody. Eur J Haematol. 2016 Aug;97(2):121-7. https://doi.org/10.1111/ejh.12691

Nadeau M, Perreault S, Seropian S, Foss F, Isufi I, Cooper DL. The use of basiliximab-infliximab combination for the treatment of severe gastrointestinal acute GvHD. Bone Marrow Transplant. 2016 Feb;51(2):273-6. https://doi.org/10.1038/bmt.2015.247

Fang J, Hu C, Hong M, Wu Q, You Y, Zhong Z, et al. Prophylactic Effects of Interleukin-2 Receptor Antagonists against Graft-versus-Host Disease Following Unrelated Donor Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2012 May;18(5):754-62. https://doi.org/10.1016/j.bbmt.2011.09.005

Kako S, Akahoshi Y, Harada N, Nakano H, Kameda K, Ugai T, et al. HLA-mismatched haploidentical transplantation using low-dose anti-thymocyte globulin (ATG: thymoglobulin. Hematology. 2017 Apr;22(3):129-135. https://doi.org/10.1080/10245332.2016.1231968

Lee KH, Lee JH, Lee JH, Kim DY, Seol M, Lee YS, et al. Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood. 2011 Sep 1;118(9):2609-17. https://doi.org/10.1182/blood-2011-02-339838

Henslee-Downey PJ, Abhyankar SH, Parrish RS, Pati AR, Godder KT, Neglia WJ, et al. Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant. Blood. 1997 May 15;89(10):3864-72.

Beatty PG, Clift RA, Mickelson EM, Nisperos BB, Flournoy N, Martin PJ, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985 Sep 26;313(13):765-71. https://doi.org/10.1056/nejm198509263131301

Law AD, Salas MQ, Lam W, Michelis FV, Thyagu S, Kim DDH, et al. Reduced-Intensity Conditioning and Dual T Lymphocyte Suppression with Antithymocyte Globulin and Post-Transplant Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplants for Hematological Malignancies. Biol Blood Marrow Transplant. 2018 Nov;24(11):2259-2264. https://doi.org/10.1016/j.bbmt.2018.07.008

Reddy N, Rezvani K, Barrett AJ, Savani BN. Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients. Biol Blood Marrow Transplant. 2011 May;17(5):591-7. https://doi.org/10.1016/j.bbmt.2010.08.007

Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, et al. Response to Rituximab-Based Therapy and Risk Factor Analysis in Epstein Barr Virus–Related Lymphoproliferative Disorder After Hematopoietic Stem Cell Transplant in Children and Adults: A Study From the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013 Sep;57(6):794-802. https://doi.org/10.1093/cid/cit391

Kalra A, Roessner C, Jupp J, Williamson T, Tellier R, Chaudhry A, et al. Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transzplantation. Clin Transplant. 2018 Jan;32(1).

Longo D L, Dierickx D, Habermann T M. Post-Transplantation Lymphoproliferative Disorders in Adults. N Engl J Med. 2018 Feb 8;378(6):549-562. https://doi.org/10.1056/nejmra1702693

Genestier L, Fournel S, Flacher M, Assossou O, Revillard JP. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activatedlymphocytes by polyclonal antithymocyte globulins. Blood. 1998 Apr 1;91(7):2360-8.

Sano H, Mochizuki K, Kobayashi S, Ohara Y, Ito M, Waragai T, et al. T-cell-replete haploidentical stem cell transplantation using low-dose antithymocyte globulin in children with relapsed or refractory acute leukemia. Int J Hematol. 2018 Jul;108(1):76-84. https://doi.org/10.1007/s12185-018-2423-5

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2021 Wang F et al.

Downloads

Download data is not yet available.